The efficacy in aromatase inhibitors and tamoxifen on Luminal postmenopausal breast neoplasms:a systematic review
10.3760/cma.j.issn.1673-4904.2013.30.012
- VernacularTitle:芳香化酶抑制剂与他莫昔芬治疗Luminal型绝经后乳腺癌疗效的系统评价
- Author:
Min YU
;
Han QIU
;
Juan ZHANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Tamoxifen;
Aromatase inhibitors
- From:
Chinese Journal of Postgraduates of Medicine
2013;36(30):31-38
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy in aromatase inhibitors and tamoxifen on Luminal postmenopausal breast neoplasms.Methods PubMED,Science Direct,EBSCO Host,EMbase,The Cochrane Library,CNKI,CECDB and CQVIP were retrieved,the evaluation methodology included.The quality of the included studies and extracted data should be researched rigorously.Review Manager 5.0 software was used to evaluate the quality standards of randomized clinical trial (RCT).Results Twelve RCT were selected,included 2634 patients,1354 cases of treatment group (use aromatase inhibitors),1280cases of control group (use tamoxifen).The results of the evaluation of the system:compared to control group,treatment group significantly improved disease-free survival in 1 year (RR =1.10,95％ CI 1.01-1.19),disease-free survival in 3 years (RR =1.09,95％ CI 1.05-1.13),the overall efficiency in 1 year (RR =1.21,95％ CI 1.12-1.30),furthermore treatment group significantly reduced the incidence of cardiovascular diseases in 3 years (RR =0.47,95％ CI 0.27-0.83),but there was no significant difference in the incidence of bone and joint disease in 3 years between the 2 groups (RR =0.99,95％ CI 0.61-1.61).Conclusion Compared to tamoxifen,the efficacy of aromatase inhibitors is excellent in treatment of Luminal postmenopausal breast neoplasms,it is worth promoting.
